PDI

PDI, Inc. has appointed David N. Stievater to the newly created position of senior vice president, emerging pharma, reporting to Michael Marquard, chief executive officer. Mr. Stievater will also serve on the executive committee.

Mr. Stievater joins the company from ImpactRx where he served as vice president of sales and vice president of business development, and was a member of the executive team. Prior to ImpactRx, he spent several years providing consulting services including marketing decision support to the biopharmaceutical industry, and concluded an 11-year tenure with the Monitor Company Group as partner and global account manager. He has advised pharmaceutical clients on such issues as sales force strategy and multi-channel physician marketing. Mr. Stievater began his career as a financial analyst at Merrill Lynch & Co.

Michael Marquard, PDI’s chief executive officer, stated, “We are delighted to have David join PDI as part of the management team. David is a highly credentialed executive who brings extensive business development expertise within the pharmaceutical industry, including emerging companies, which is an essential part of PDI’s growth strategy.”

Mr. Stievater stated, “This is a very exciting time to be joining PDI. As the pharmaceutical industry model continues to evolve, there is tremendous opportunity to better serve a wider range of companies with value added sales and marketing services. PDI’s expanded focus on earlier stage biotech and pharmaceutical clients establishes a broader base for solid growth. I look forward to having a significant impact on that effort.”